摘要
动脉化疗栓塞术(TACE)是中期肝癌患者的主要治疗方法。但是,由于这种技术存在着种种缺陷,比如药物局部释放的不可控制性、全身不良反应等,限制了其临床应用。而新出现的药物缓释微球(drug-eluting beads,DEB)可以负载着阿霉素应用于TACE中,不仅可以长时间维持化疗药物的局部浓度,达到更高的客观反应率,并且降低了不良反应的发生率,从而使患者获益。目前,药物缓释微球动脉化疗栓塞术(DEB-TACE)在国外已经得到了广泛的应用和推广,更多的相关临床试验也正在进行中。本文针对DEB-TACE的特性及最新研究进展予以综述。
Transarterial chemoembolization（TACE） has been the main treatment for patients with intermediate-stage hepatocellular carcinoma（HCC）.However,the clinical application of TACE is limited due to the technical deficiencies,such as uncontrolled local drug delivery and systemic toxicity.Recently,the new drug-eluting beads（DEB）,loading with doxorubicin,have be used in the TACE procedures.This new technique can not only maintain the local drug level for quite a long time and thus get a higher objective response,but also decrease the systemic toxicity.Transarterial chemoembolization with drug-eluting beads（DEB-TACE） have already been widely used abroad,and more related clinical trials are underway to clarify its advantages.This paper aims to make a comprehensive review in the respects of its characteristics and the latest research progress in DEB-TACE.（J Intervent Radiol,2012,21： 79-83）
出处
《介入放射学杂志》
CSCD
北大核心
2012年第1期79-83,共5页
Journal of Interventional Radiology
关键词
肝癌
经导管动脉化疗栓塞术
药物缓释微球
hepatocellular carcinoma
transarterial chemoembolization
drug-eluting bead
